Oncogenesis · 2024 · 13 citations · 41 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionApoptosis ResistanceCancer Cell SignalingColorectal CancerOncogenic Signaling PathwaysSignal Transduction In CancerBasic Leucine Zipper DomainsCancer Signaling PathwaysDickkopf ProteinsLeucine Zipper ProteinsMicrotubule-associated Protein 4Oxaliplatin-based TherapyProtein Kinase InhibitorsSecreted Protein Identification
Oxaliplatin is effective against colorectal cancer (CRC), but resistance hampers treatment. We found upregulated Dickkopf-1 (DKK1, a secreted protein) in oxaliplatin-resistant (OR) CRC cell lines and DKK1 levels increased by more than 2-fold in approximately 50% of oxaliplatin-resistant CRC tumors. DKK1 activates AKT via cytoskeleton-associated protein 4 (CKAP4, a DKK1 receptor), modulating oxaliplatin responses in vitro and in vivo. The leucine zipper (LZ) domain of CKAP4 and cysteine-rich domain 1 (CRD1) of secreted DKK1 are crucial for their interaction and AKT signaling. By utilizing the LZ protein, we disrupted DKK1 signaling, enhancing oxaliplatin sensitivity in OR CRC cells and xenograft tumors. This suggests that DKK1 as a chemoresistant factor in CRC via AKT activation. Targeting DKK1 with the LZ protein offers a promising therapeutic strategy for oxaliplatin-resistant CRC with high DKK1 levels. This study sheds light on oxaliplatin resistance mechanisms and proposes an innovative intervention for managing this challenge.
41
Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction
Andrei Glinka, Wei Wu, Hajo Delius et al. · Nature · 1998 · 1.6K citations
LDL-receptor-related protein 6 is a receptor for Dickkopf proteins
Bingyu Mao, Wei Wu, Yan Li et al. · Nature · 2001 · 1K citations
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima et al. · Blood · 2009 · 398 citations · Full text
Medicine, Immunology, Oncology +10